Christopher Sweeney
Professor of Medicine at Harvard Medical School
Biography
Harvard Medical School
Christopher J. Sweeney, MBBS, is a Medical Oncologist at the Dana-Farber Cancer Institute. He is a member of the American Society of Clinical Oncology, the Eastern Cooperative Oncology Group-ACRIN, Alliance and the American Association for Cancer Research. Dr. Sweeney’s primary research interest is drug discovery and development. His academic focus is management of genitourinary malignancies, with a focus on prostate and testicular cancer. Dr. Sweeney is a highly active contributor to his field, having served on the Editorial Board for ASCO’s “Journal of Clinical Oncology†and the Program and Cancer Education Committees of the American Society of Clinical Oncology. He has received peer reviewed funding from the National Institutes of Health and the Department of Defense. Dr. Sweeney is also a member of the Scientific Advisory Boards of biotech companies in the United States and Australia. Dr. Sweeney received his medical degree from the University of Adelaide, South Australia in 1992 and completed an internship at the Royal Adelaide Hospital. He did residency in internal medicine at Gundersen Lutheran Medical Center, La Crosse, Wisconsin and a fellowship in Hematology/Oncology at Indiana University Medical Center, where he was later appointed Associate Director for Clinical Research for the Simon Cancer Center. Dr. Sweeney joined the Lank Center for Genitourinary Oncology at DFCI and Harvard Medical School in 2009.
Videos
Expert Discusses Safety Profile from the ENZAMET Trial
Is there still a role for docetaxel in mHSPC?
Dr. Sweeney on the Phase III ENZAMET Trial in Metastatic Hormone-Sensitive Prostate Cancer
Dr. Sweeney Discusses Tailoring Treatment in Prostate Cancer
Dr. Christopher Sweeney -- ASCO 2014 | Dana-Farber Cancer Institute
Dr. Sweeney on the Future of Prostate Cancer Research
IPATential150 shows promise of ipatasertib addition in some mCRPC patients | Christopher Sweeney
Dr. Sweeney on Chemotherapy in Prostate Cancer
Dr. Sweeney on Chemotherapy Versus Abiraterone for mCRPC
Researcher comment: OS boost with enzalutamide in metastatic CSPC setting | Christopher Sweeney
Dr. Christopher Sweeney on treating genitourinary cancers | Dana-Farber Cancer Institute
STAMPEDE: Docetaxel for Hormone-Naive Prostate Cancer
Prolonging survival in early chemo-sensitive populations - Christopher Sweeney
Dr. Sweeney on the Optimal Use of Cabazitaxel
Prostate Cancer Research at ESMO 2020: Christopher Sweeney, MBBS
Read about executive education
Other experts
Popular Courses
Looking for an expert?
Contact us and we'll find the best option for you.